Maetrics acquires High Edge Consulting

Published: 3-Oct-2013

US professional consulting firm gains a base in the UK and Europe

High Edge Consulting, a UK-based provider of regulatory and quality assurance assistance for the medical device industry, has been sold to Maetrics LLC, a US-based professional consulting firm for FDA regulated industries, for an undisclosed sum.

The complementary strengths of the two businesses will be integrated to support the growth of Maetrics as well as providing the firm with a strategic base in the UK and Europe.

High Edge Consulting will be renamed Maetrics Ltd and will continue to be based at BioCity Nottingham serving the same clients, but with Maetrics' support.

Established in 2002, High Edge Consulting has on average grown by 52% year-on-year since 2009 and expects to realise further growth opportunities. This includes the immediate recruitment of five new people for office positions.

Founder and Managing Director of High Edge Consulting, Peter Rose, and Director, Louisa Rose, will remain as full-time directors.

Indianapolis-based Maetrics provides compliance and quality services to the life sciences industry, including markets such as medical devices, pharmaceutical, biotech and nutritional industries. It has experienced double-digit growth over the past three years.

George Huntley, Chief Operating Officer of Maetrics, said: 'We are delighted to announce that the acquisition of High Edge Consulting is complete.

'We have been working closely with the High Edge team on a large project in Europe for a number of months. This acquisition brings our partnership to a new level and solidifies a great cultural fit between the two companies.'

Peter Rose, Managing Director and Founder of High Edge Consulting commented: 'Maetrics shares our vision for the direction of the business and I am very excited about working with our US colleagues to grow the business in the UK and Europe.'

As a combined entity the company will provide compliance and quality services to companies spanning the entire life sciences industry – including markets such as medical devices, pharmaceutical, biotech, nutritional and other FDA and Notified Body-regulated industries.

You may also like